Genesis of hepatic fibrosis and its biochemical markers

References

• Friedman S. L., Bansal M. B. Reversal of hepatic fibrosis: fact or fantasy. Hepatology 2006; 43: S82–8
   PubMed Web of Science ®Google Scholar
• Kisseleva T., Brenner D. A. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21(Suppl 3)S84–7
   PubMed Web of Science ®Google Scholar
• Friedman S. L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247–50
   PubMed Web of Science ®Google Scholar
• Alcolado R., Arthur M. J., Iredale J. P. Pathogenesis of liver fibrosis. Clin Sci (Lond) 1997; 92: 103–12
   PubMed Web of Science ®Google Scholar
• Sarem M., Znaidak R., Macias M., Rey R. Hepatic stellate cells: their role in normal and pathological conditions. Gastroenterol Hepatol 2006; 29: 93–101
   PubMedGoogle Scholar
• Reeves H. L., Friedman S. L. Activation of hepatic stellate cells – a key issue in liver fibrosis. Front Biosci 2002; 7: d808–26
   PubMed Web of Science ®Google Scholar
• Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002; 7: d1899–914
   PubMed Web of Science ®Google Scholar
• Bataller R., Paik Y. H., Lindquist J. N., Lemasters J. J., Brenner D. A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004; 126: 529–40
   PubMed Web of Science ®Google Scholar
• Efsen E., Grappone C., DeFranco R. M., Milani S., Romanelli R. G., Bonacchi A., et al. Up‐regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002; 37: 39–47
   PubMed Web of Science ®Google Scholar
• Paik Y. H., Schwabe R. F., Bataller R., Russo M. P., Jobin C., Brenner D. A. Toll‐like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043–55
   PubMed Web of Science ®Google Scholar
• LeCouter J., Moritz D. R., Li B., Phillips G. L., Liang X. H., Gerber H. P., et al. Angiogenesis‐independent endothelial protection of liver: role of VEGFR‐1. Science 2003; 299: 890–3
   PubMed Web of Science ®Google Scholar
• Olaso E., Salado C., Egilegor E., Gutierrez V., Santisteban A., Sancho‐Bru P., et al. Proangiogenic role of tumor‐activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003; 37: 674–85
   PubMed Web of Science ®Google Scholar
• Ankoma‐Sey V., Wang Y., Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000; 31: 141–8
   PubMed Web of Science ®Google Scholar
• Edwards D. R., Murphy G., Reynolds J. J., Whitham S. E., Docherty A. J., Angel P., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899–904
   PubMed Web of Science ®Google Scholar
• Rachfal A. W., Brigstock D. R. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26: 1–9
   PubMed Web of Science ®Google Scholar
• Miyahara T., Schrum L., Rippe R., Xiong S., Yee H. F Jr., Motomura K., et al. Peroxisome proliferator‐activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715–22
   PubMed Web of Science ®Google Scholar
• Kim K. H., Kim H. C., Hwang M. Y., Oh H. K., Lee T. S., Chang Y. C., et al. The antifibrotic effect of TGF‐beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun 2006; 343: 1072–8
   PubMed Web of Science ®Google Scholar
• Zhan S. S., Jiang J. X., Wu J., Halsted C., Friedman S. L., Zern M. A., et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435–43
   PubMed Web of Science ®Google Scholar
• Inagaki Y., Kushida M., Higashi K., Itoh J., Higashiyama R., Hong Y. Y., et al. Cell type‐specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology 2005; 129: 259–68
   PubMed Web of Science ®Google Scholar
• Uemura M., Swenson E. S., Gaca M. D., Giordano F. J., Reiss M., Wells R. G. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha‐smooth muscle actin organization. Mol Biol Cell 2005; 16: 4214–24
   PubMed Web of Science ®Google Scholar
• Tsukada S., Westwick J. K., Ikejima K., Sato N., Rippe R. A. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor‐beta‐stimulated hepatic stellate cells. J Biol Chem 2005; 280: 10055–64
   PubMed Web of Science ®Google Scholar
• Schuppan D., Ruehl M., Somasundaram R., Hahn E. G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351–72
   PubMed Web of Science ®Google Scholar
• Lauria V., Tariciotti G., Festuccia F., Attili A. F. The physiopathological mechanism of hepatic fibrosis. Minerva Gastroenterol Dietol 1998; 44: 149–58
   PubMedGoogle Scholar
• Iredale J. P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427–36
   PubMed Web of Science ®Google Scholar
• Iredale J. P., Benyon R. C., Arthur M. J., Ferris W. F., Alcolado R., Winwood P. J., et al. Tissue inhibitor of metalloproteinase‐1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176–84
   PubMed Web of Science ®Google Scholar
• Roeb E., Purucker E., Breuer B., Nguyen H., Heinrich P. C., Rose‐John S., et al. TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol 1997; 27: 535–44
   PubMed Web of Science ®Google Scholar
• Schaefer B., Rivas‐Estilla A. M., Meraz‐Cruz N., Reyes‐Romero M. A., Hernandez‐Nazara Z. H., Dominguez‐Rosales J. A., et al. Reciprocal modulation of matrix metalloproteinase‐13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 2003; 162: 1771–80
   PubMed Web of Science ®Google Scholar
• Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M., Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446–51
   PubMed Web of Science ®Google Scholar
• Preaux A. M., Mallat A., Nhieu J. T., D'Ortho M. P., Hembry R. M., Mavier P. Matrix metalloproteinase‐2 activation in human hepatic fibrosis regulation by cell–matrix interactions. Hepatology 1999; 30: 944–50
   PubMed Web of Science ®Google Scholar
• Xu G. F., Li P. T., Wang X. Y., Jia X., Tian D. L., Jiang L. D., et al. Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats. World J Gastroenterol 2004; 10: 3621–7
   PubMed Web of Science ®Google Scholar
• Murawaki Y., Ikuta Y., Okamoto K., Koda M., Kawasaki H. Serum matrix metalloproteinase‐3 (stromelysin‐1) concentration in patients with chronic liver disease. J Hepatol 1999; 31: 474–81
   PubMed Web of Science ®Google Scholar
• Zhu Y. K., Wang B. E., Shen F. J., Wang A. M., Jia J. D., Ma H. Dynamic evolution of MMP‐13, TIMP‐1, type I and III collagen and their interaction in experimental liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2004; 12: 612–15
   PubMedGoogle Scholar
• Zhou X., Hovell C. J., Pawley S., Hutchings M. I., Arthur M. J., Iredale J. P., et al. Expression of matrix metalloproteinase‐2 and ‐14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2004; 24: 492–501
   PubMed Web of Science ®Google Scholar
• Bataller R., Sancho‐Bru P., Gines P., Brenner D. A. Liver fibrogenesis: a new role for the renin‐angiotensin system. Antioxid Redox Signal 2005; 7: 1346–55
   PubMed Web of Science ®Google Scholar
• Borkham‐Kamphorst E., Herrmann J., Stoll D., Treptau J., Gressner A. M., Weiskirchen R. Dominant‐negative soluble PDGF‐beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766–77
   PubMed Web of Science ®Google Scholar
• Gabele E., Reif S., Tsukada S., Bataller R., Yata Y., Morris T., et al. The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 2005; 280: 13374–82
   PubMed Web of Science ®Google Scholar
• Geremias A. T., Carvalho M. A., Borojevic R., Monteiro A. N. TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol 2004; 4: 30
   PubMed Web of Science ®Google Scholar
• Cai W. M., Zhang B. B., Weng H. L., Hu Z. R., Lv J., Zheng M., et al. [The diagnostic value of eight serum indices for liver fibrosis. ] Zhonghua Gan Zang Bing Za Zhi 2004; 12: 219–22
   PubMedGoogle Scholar
• Campbell J. S., Hughes S. D., Gilbertson D. G., Palmer T. E., Holdren M. S., Haran A. C., et al. Platelet‐derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389–94
   PubMed Web of Science ®Google Scholar
• Arthur M. J., Iredale J. P. Hepatic lipocytes, TIMP‐1 and liver fibrosis. J R Coll Phys Lond 1994; 28: 200–8
   PubMedGoogle Scholar
• Neubauer K., Saile B., Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol 2001; 15: 187–93
   PubMed Web of Science ®Google Scholar
• Desmet V. J., Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40: 860–7
   PubMed Web of Science ®Google Scholar
• Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alpha‐2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–13
   PubMed Web of Science ®Google Scholar
• Issa R., Zhou X., Constandinou C. M., Fallowfield J., Millward‐Sadler H., Gaca M. D., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross‐linking. Gastroenterology 2004; 126: 1795–808
   PubMed Web of Science ®Google Scholar
• Wai C. T., Greenson J. K., Fontana R. J., Kalbfleisch J. D., Marrero J. A., Conjeevaram H. S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26
   PubMed Web of Science ®Google Scholar
• Das S. K., Dhanya L., Vasudevan D. M. Biomarkers of alcoholism: an updated review. Scand J Clin Lab Invest 2007, In press
   PubMed Web of Science ®Google Scholar
• Das S. K., Balakrishnan V., Vasudevan D. M. Utility of serum hydroxyproline, type IV collagen and AST to platelet ratio index (APRI) in the prediction of liver damage. Clin Chem 2007; S6: A77, [abstract]
   Google Scholar
• Sud A., Hui J. M., Farrell G. C., Bandara P., Kench J. G., Fung C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance as probability index. Hepatology 2004; 39: 1239–47
   PubMed Web of Science ®Google Scholar
• Cales P., Oberti F., Michalak S., Hubert‐Fouchard I., Rousselet M. C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373–81
   PubMed Web of Science ®Google Scholar
• Adinolfi L. E., Giordano M. G., Andreana A., Tripodi M. F., Utili R., Cesaro G., et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haemotol 2001; 113: 590–5
   PubMed Web of Science ®Google Scholar
• Kamimoto Y., Horiuchi S., Tanase S., Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isoenzymes; evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5: 367–75
   PubMed Web of Science ®Google Scholar
• Nandi A., Estess P., Siegelman M. H. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000; 275: 14939–48
   PubMed Web of Science ®Google Scholar
• Vrochides D., Papanikalaou V., Pertoft H., Antoniads A. A., Heldin P. Biosynthesis and degradation of hyaluranon by non‐parenchymal liver cells during liver regeneration. Hepatology 1996; 23: 1650–5
   PubMed Web of Science ®Google Scholar
• Fraser J. R., Gibson P. R. Mechanisms by which food intake elevated circulating levels of hyaluronan in humans. J Intern Med 2005; 258: 460–6
   PubMed Web of Science ®Google Scholar
• Kelleher T. B., Mehta S. H., Bhaskar R., Sulkowski M., Astemborski J., Thomas D. L., et al. Prediction of hepatic fibrosis in HIV/HCV co‐infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43: 78–84
   PubMed Web of Science ®Google Scholar
• Kivirikko K. I. Collagens and their abnormalities in a wide spectrum of diseases. Ann Med 1993; 25: 113–26
   PubMed Web of Science ®Google Scholar
• Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., Giboudeau J. Diagnostic accuracy of hyaluronan and type 3 procollagen amino‐terminal peptide serum assays as markers of liver fibrosis in chronic hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558–63
   PubMed Web of Science ®Google Scholar
• Gabrielli G. B., Corrocher R. Hepatic fibrosis and its serum markers: a review. Dig Dis Sci 1991; 9: 303–16
   Web of Science ®Google Scholar
• Maruyama K., Okazaki I., Takagi T., Ishii H. Formation and degradation of basement membrane collagen. Alcohol Alcohol Suppl 1991; 1: 369–74
   PubMedGoogle Scholar
• Santos V. N., Leite‐Mor M. M., Kondo M., Martins J. R., Nader H., Lanzoni V. P., et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non‐alcoholic fatty liver disease. Braz J Med Biol Res 2005; 38: 747–53
   PubMed Web of Science ®Google Scholar
• Lee H. S., Shun C. T., Chiou L. L., Chen C. H., Huang G. T., Sheu J. C. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J Gastroenterol Hepatol 2005; 20: 1109–14
   PubMed Web of Science ®Google Scholar
• Wyszomirska R. M., Nishimura N. F., Almeida J. R., Yamanaka A., Soares E. C. High serum laminin and type IV collagen levels in schistosomiasis mansoni. Arq Gastroenterol 2005; 42: 221–5
   PubMedGoogle Scholar
• Tsukamoto T., Yamamoto T., Ikebe T., Takemura S., Shuto T., Kubo S., et al. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver. Hepatogastroenterology 2004; 51: 777–80
   PubMedGoogle Scholar
• Hirayama C., Suzuki H., Takada A., Fujisawa K., Tanikawa K., Igarashi S. Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide. J Gastroenterol 1996; 31: 242–8
   PubMed Web of Science ®Google Scholar
• Ponmarenko Y., Anna Leo M., Kroll W., Lieber C. S. Effects of alcohol consumption on 8 circulating markers of liver fibrosis. Alcohol Alcohol 2002; 37: 252–5
   PubMed Web of Science ®Google Scholar
• Murphy F. R., Issa R., Zhou X., Ratnarajah S., Nagase H., Arthur M. J., et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase‐1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069–76
   PubMed Web of Science ®Google Scholar
• Tsukada S., Parsons C. J., Rippe R. A. Mechanism of liver fibrosis. Clin Chem Acta 2006; 364: 33–60
   PubMed Web of Science ®Google Scholar
• Johansen J. S., Christoffersen P., Moller S., Price P. A., Henriksen J. H., Garbarsch C., et al. Serum YKL‐40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911–20
   PubMed Web of Science ®Google Scholar
• Bigg H. F., Wait R., Rowan A. D., Cawston T. E. The mammalian chitinase – like lectin, YKL‐40, binds specifically to type 1 collagen and modulates the rate of type 1 collagen fibril formation. J Biol Chem 2006; 281: 210282–95
   Web of Science ®Google Scholar
• Johansen J. S., Jensen B. V., Roslind A., Nielsen D., Price P. A. Serum YKL‐40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev 2006; 15: 194–202
   PubMed Web of Science ®Google Scholar
• Chen Y., Wang B. E., Jia J. D., Qian L. X., Wang T. L., Chen M. H., et al. Noninvasive evaluation of liver fibrosis in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 354–7
   PubMedGoogle Scholar
• Liu J., Wang J. Y., Lu Y. Serum fibrosis markers in diagnosing liver fibrosis. Zhonghua Nei Ke Za Zhi 2006; 45: 475–7
   PubMedGoogle Scholar
• Patel K., Gordon S. C., Jacobson I., Hezode C., Oh E., Smith K. M., et al. Evaluation of a panel of non‐invasive serum markers to differentiate mild from advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935–42
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Sorrell M. F. Noninvasive tests for liver fibrosis. Semin Liver Dis 2006; 26: 337–47
   PubMed Web of Science ®Google Scholar
• Rosenberg W. M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–13
   PubMed Web of Science ®Google Scholar
• Adams L. A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867–73
   PubMed Web of Science ®Google Scholar
• Kawamoto M., Mizuguchi T., Katsuramaki T., Nagayama M., Oshima H., Kawasaki H., et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006; 12: 4325–30
   PubMed Web of Science ®Google Scholar
• McClain C., Barve S., Joshi‐Barve S., Song Z., Deaciuc I., Chen T., et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005; 29: 180S—8S
   PubMed Web of Science ®Google Scholar
• Kanzler S., Baumann M., Schirmacher P., Dries V., Bayer E., Gerken G., et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor‐beta. J Viral Hepatol 2001; 8: 430–7
   PubMed Web of Science ®Google Scholar
• Akpolat N., Yahsi S., Godekmerdan A., Demirbag K., Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gasteroenterol 2005; 11: 3260–3
   PubMed Web of Science ®Google Scholar
• Musso G., Gambino R., Biroli G., Carello M., Faga E., Pacini G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta‐cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438–46
   PubMed Web of Science ®Google Scholar
• Day C. P. Genetic studies to identify hepatic fibrosis genes and SNP's in human populations. Methods Mol Med 2005; 117: 315–31
   PubMedGoogle Scholar
• Patel K., Norris S., Lebeck L., Feng A., Clare M., Pianko S., et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006; 43: 241–9
   PubMed Web of Science ®Google Scholar
• Bataller R., North K. E., Brenner Da. Genetic polymorphism and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493–503
   PubMed Web of Science ®Google Scholar
• Kamal S. M., Turner B., He Q., Rasenack J., Bianchi L., Al Tawil A., et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006; 43: 771–9
   PubMed Web of Science ®Google Scholar
• Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer‐based total serum protein glycomics. Nat Med 2004; 10: 429–34
   PubMed Web of Science ®Google Scholar
• Seeger C., Mason W. S. Hepatitis B virus biology. Microbial Mol Biol Rev 2000; 64: 51–68
   PubMed Web of Science ®Google Scholar
• Weiss J., Wu H., Farrenkopf B., Schultz T., Song G., Shah S., et al. Real‐time TaqMan PCR detection and quantitation of HBV genotypes A–G with the use of an internal quantitation standard. J Clin Virol 2004; 30: 86–93
   PubMed Web of Science ®Google Scholar
• Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675–84
   PubMed Web of Science ®Google Scholar
• Janssen H. L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U. S., Cakaloglu Y., et al. HBV 99‐01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa‐2b alone or in combination with lamivudine for HbeAg‐positive chronic hepatitis B: a radomised trial. Lancet 2005; 365: 123–9
   PubMed Web of Science ®Google Scholar
• Schildgen O., Sirma H., Funk A., Olotu C., Wend U. C., Hartmann H., et al. Variant of hepatitis B virus with primary resistence to adefovir. N Engl J Med 2006; 354: 1807–12
   PubMed Web of Science ®Google Scholar
• Nafa S., Ahmed S., Tavan D., Pichoud C., Berby F., Stuyver L., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078–88
   PubMed Web of Science ®Google Scholar